APFID

Home > Latest News on ID > Interesting Papers

LOGIN
CA-MRSA: what do we need to know? Clin Microbiol Infect. 2009;15 Suppl 7:17-25
Date: 2010-03-04   Read: 156053

Clin Microbiol Infect. 2009 Dec;15 Suppl 7:17-25

Community-acquired methicillin-resistant Staphylococcus aureus: what do we need to know?

Witte W

Community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) has become a matter of concern worldwide, in particular in the USA. For the analysis of emergence and spread, clear definitions based on epidemiological origin are needed for discrimination between CA-MRSA, healthcare-associated community MRSA, and healthcare-associated MRSA (HA-MRSA). Although its role in pathogenesis is currently under debate, the capability for Panton-Valentine leukocidin formation is associated with the majority of CA-MRSA isolates from North America and from Europe. Most CA-MRSA isolates are attributed to clonal lineages different from HA-MRSA; there are, however, clonal lineages from which both HA-MRSA and CA-MRSA have been reported (e.g. ST1, ST5, ST8, and ST22); CA-MRSA ST8 (USA300), which is most frequent in the USA, has meanwhile been reported from Europe. CA-MRSA ST80 is widely disseminated in Europe; because of its pronounced oxacillin heteroresistance phenotype, cefoxitin-based assays are advisable for reliable detection. So far, CA-MRSA infections seem to be much less frequent in Europe than in the USA, where patients with particular predispositions and low social status are at especial risk.



Next Excess costs and utilization associated with methicillin resistance for patients with S. aureus infection. Infect Control Hosp Epidemiol. 2010;31(4): 2010-03-12 155300
Previous Geographic distribution of S. aureus causing invasive infections in Europe: a molecular-epidemiological analysis. PLoS Med. 2010;7(1):e1000215 2010-03-03 156187
޴ٷΰ ΰ